Clinical Trial: A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07842497) titled 'A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis' on Sept. 14.

Brief Summary: It is a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanized monoclonal antibody injection in subjects with acute gout flare

Study Start Date: Oct. 28

Study Type: INTERVENTIONAL

Condition: Acute Gouty Arthritis

Intervention: DRUG: Compound Betamenth Group

Intramuscular injection 2ml/bottle

DRUG: IBI3011 GROUP

Subcutaneous injection 300mg/bottle

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Published by HT Digital Co...